Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H32O2S |
| Molecular Weight | 288.489 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCSCC(O)=O
InChI
InChIKey=IPBCWPPBAWQYOO-UHFFFAOYSA-N
InChI=1S/C16H32O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-15-16(17)18/h2-15H2,1H3,(H,17,18)
Tetradecylthioacetic acid (TTA) is a hypolipidemic antioxidant with immunomodulating properties involving activation of peroxisome proliferator-activated receptors (PPARs). TTA exerts both hypolipidemic and anti-inflammatory effects in psoriasis patients - TTA can be of therapeutic benefit for a subgroup of psoriatic patients. TTA may improve myocardial function in heart failure, potentially involving its ability to decrease the availability of free fatty acids in plasma and increase the myocardial proportion of n-3 polyunsaturated fatty acids. TTA attenuates dyslipidemia in patients with type 2 diabetes mellitus. These effects may occur through mechanisms involving PPAR-alpha and PPAR-delta activation, resulting in increased mitochondrial fatty acid oxidation.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. | 1994 Dec 9 |
|
| Transient up-regulation of liver mitochondrial thymidine kinase activity in proliferating mitochondria. | 2001 Feb |
|
| Growth reduction in glioma cells after treatment with tetradecylthioacetic acid: changes in fatty acid metabolism and oxidative status. | 2001 Mar 15 |
|
| Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. | 2001 May |
|
| Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. | 2001 Nov |
|
| Tetradecylthioacetic acid reduces stenosis development after balloon angioplasty injury of rabbit iliac arteries. | 2001 Oct |
|
| Inhibition of rat lipoprotein oxidation after tetradecylthioacetic acid feeding. | 2002 Mar 15 |
|
| Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression: evidence for peroxisome proliferator-activated receptor-alpha independent induction of UCP-2 expression. | 2003 Aug 15 |
|
| Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. | 2003 Jul |
|
| The metabolic effects of thia fatty acids in rat liver depend on the position of the sulfur atom. | 2005 Jun 30 |
|
| Effect of 18:1n-9, 20:5n-3, and 22:6n-3 on lipid accumulation and secretion by Atlantic salmon hepatocytes. | 2005 May |
|
| A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia. | 2006 Jun 1 |
|
| Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. | 2006 Oct |
|
| Phospholipid molecular species, beta-oxidation, desaturation and elongation of fatty acids in Atlantic salmon hepatocytes: effects of temperature and 3-thia fatty acids. | 2006 Sep |
|
| Does the capacity for energy utilization affect the survival of post-smolt Atlantic salmon, Salmo salar L., during natural outbreaks of infectious pancreatic necrosis? | 2007 Jul |
|
| Effect of dietary tetradecylthioacetic acid on colon cancer growth studied by dynamic contrast enhanced MRI. | 2007 Nov |
|
| Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study. | 2008 Apr |
|
| Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension. | 2008 Feb |
|
| Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome. | 2009 Feb 26 |
|
| Platelet activating factor stimulates arachidonic acid release in differentiated keratinocytes via arachidonyl non-selective phospholipase A2. | 2010 Apr |
|
| Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPAR alpha selective. | 2010 Feb 1 |
|
| Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. | 2010 Jan |
|
| Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment. | 2012 |
Patents
Sample Use Guides
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2921-20-2
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
DTXSID0040759
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
114924
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
7ZU5I25S2O
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
TETRADECYLTHIOACETIC ACID
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
